Category Archives: Stell Cell Research


Combined adipose-derived mesenchymal stem cell and antibiotic … – Nature.com

Bacteria and biofilm formation

MSSA strain ATCC29213 (American Type Culture Collection, Manassas, VA, USA) was used as it tends to form biofilms32,33. MSSA was streaked onto plates containing tryptic soy broth and Bacto agar (BD Biosciences, Franklin Lakes, NJ, USA) and grown overnight in 5 mL of tryptic soy broth at 37 C in a shaking incubator. MSSA cells in the incubation medium were grown to the early exponential growth phase (0.20.3 optical density at 600 nm), corresponding to 5.0 107 CFU/mL.

Adipose tissue (~1.5 g) was obtained from Wistar rats (female; 12 weeks old; Japan SLC Corp., Shizuoka, Japan). ADSCs were prepared by modifying previously reported methods34. Further details can be found in the Supplementary file. Cellular characteristics (i.e. expression of stem cell surface markers) were determined using flow cytometric analysis after labeling ADSCs with appropriate antibodies of cultivation.

Wistar rats (female; 12 weeks old; Japan SLC Corp.) were housed under specific pathogen-free conditions with a 12-h light/dark cycle and ad libitum access to a certified diet (CRF-1; Oriental Yeast Corp., Tokyo, Japan) and water (chlorine concentration; 10 ppm). The drinking, feeding behavior, and body weight of the rats were monitored regularly. The animals were acclimatized for 7 days before undergoing the implant operation.

Rats were anesthetized with midazolam (2.5 mg/kg; Astellas Pharma, Tokyo, Japan), medetomidine (0.5 mg/kg; Zenoaq, Fukushima, Japan), and butorphanol tartrate (2.5 mg/kg; Meiji Seika Pharma, Tokyo, Japan). To establish infection, A medical-grade K-wire (1.2 mm diameter; Synthes Inc., West Chester, PA, USA) was incubated in an overnight culture with MSSA strain ATCC29213 and then air-dried for 20min prior to insertion. This MSSA strain exposure coats the screw with 5107 CFU. The K-wire was surgically placed into the distal femur as previously described34,35,36. Briefly, the skin overlying the leg was shaved and cleaned with iodine solution. A medial parapatellar approach was used, and the patella was dislocated laterally to access the knee joint. The femoral medullary canal was reamed with an 18-gauge needle and the K-wire was placed in a retrograde fashion with 1 mm of the wire protruding into the joint space. The quadriceps-patellar complex was reduced to the anatomic position, and the wound was closed with nylon 4-0 sutures. Rats were randomly assigned and equally divided into three groups: no-treatment, antibiotic (ciprofloxacin [3.0 mg/kg per day intravenously]), and ADSCs [5.0 105 cells intravenously 30 min, 6 h, and 18 h after the surgical procedure]) with antibiotic (ciprofloxacin [3.0 mg/kg per day intravenously] groups. The ADSC dose, based on a previous report37, is considered to not induce adverse effects, including a high mortality rate. Additionally, a previous report showed that a ciprofloxacin dose of 3.0 mg/kg per day caused no adverse effects or unstable conditions in rats11. MSSA induced infection in 100% of the untreated rats with no significant differences in the initial body weights between the different groups.

After evaluating the general overall condition and soft tissue swelling, the rats were euthanized on POD 14 using thiopental sodium (100 mg/kg body weight). Tissues from the knee joint space, femur, and implant were harvested in a sterile manner for ex vivo analyses.

Weight change (n = 6 rats per group) was calculated as a percentage change based on the preoperative weight to quantitatively measure the systemic response to infection. Preoperative baseline measurements were performed on the day before surgery. The weight of the rats was also evaluated on PODs 1, 3, 7, and 14.

Soft tissue and bone damage (n = 6 rats per group) on POD14 was scored by three examiners (D.I, A.T. and T.K.) blinded to the rats according to a modified Rissing scoring38,39. Further details can be found in Supplementary file.

CT imaging (n = 6 rats per group) was performed on POD14 to determine the degree of infection within the femoral region of interest. Considering that image artifacts from the K-wires may cause artifacts in the reconstructed CT images, isolated femurs from rats with the wire removed were subjected to CT scanning (LaTheta LCT-200; Hitachi Aloka Medical, Tokyo, Japan), operating at 50 kV and 0.5 mA (radiation exposure remained below 40 mSv). BMD was calculated automatically using LaTheta software (version 3.51). Reconstructed CT images were initially visualized in three dimensions (3D) to evaluate changes in bone morphology resulting from implant infection. A threshold-limited 3D rendering was created to visualize bone damage.

Implants were harvested (n = 6 rats per group) from each group. Based on a previous report, the bacterial burden on the implants was determined using a CFU assay40,41. To quantify living bacteria adherent to the implant within the biofilm, the removed implants were placed individually into 1.5-mL microtubes containing PBS (1 mL at 4C), vortexed for 15 s and sonicated for 5 min at 40 Hz in a water bath (Bransonic 5210; Branson Ultrasonics, Brookfield, CT, USA), followed by an additional 1 min of vortexing. The spread plate method was used to quantitatively evaluate the biofilm; the solution containing each bacterium from the biofilm was serially diluted 10-fold with PBS, followed by culturing on an agar plate at 37C for 24 h. MSSA was cultured on tryptic soy broth agar plates. The bacterial CFUs obtained from the implant were determined by counting the CFUs after culturing on plates overnight.

At the established endpoint (POD14), the femurs isolated from the rats were fixed in 10% neutralized formalin solution and dehydrated using an ethanol gradient (70%, 80%, 90%, and 100%). The fixed specimens were decalcified in 10% formic sodium citrate solution, embedded in paraffin, and sectioned in the coronal plane. The sections were stained with hematoxylin and eosin, and the slides were observed using an optical microscope (Biorevo BZ-9000; Keyence Corp., Osaka, Japan).

At the established endpoint (POD14), total RNA was extracted from the knee tissue of the rats (n = 6 rats per group). The mRNA expression of rCRAMP, TNF-, IL-6 and IL-1b was evaluated by quantitative PCR. All values were normalized to the level of the GAPDH gene, and relative gene expression levels were calculated using the 2Ct method42. Further details can be found in the Supplementary file (Supplementary Table S1).

Tissue sections were evaluated to determine the location of ADSCs following injection. To confirm the location of the injected ADSCs, they were labeled with the fluorescent dye DiI (Vybrant DiI Cell Labeling Solution; Life Technologies, Carlsbad, CA, USA) before injection. DiI binds to cellular thiols and has long-term stability, enabling the tracing of DiI-labeled transplanted cells in the host tissue. The concentration of ADSCs was adjusted to 5.0 105 cells/mL; DiI (5 L/mL) was dissolved in the cell culture media and incubated for 15 min at 37C in a 5% CO2 incubator for ADSCs labeling. The filtrate was centrifuged at 180g for 5 min at 25C and the supernatant was removed to separate the DiI from the filtrate. The ADSCs were centrifuged twice with Dulbeccos modified Eagle medium under the same conditions and the supernatant was removed. We used separate rats for this experiment (n = 3 rats per antibiotic group and DiI-labeled ADSCs with antibiotic group). On day 14 post-injection, a frozen section was prepared using Kawamotos film method in the sagittal plane43. For identification of tissues following DiI labeling, the gray-scale scale (16 bit) of the DiI-labeled section was used.

All continuous variables were assessed for normality using the ShapiroWilk test. Normally distributed data were expressed as the mean standard error. Data were analyzed using SPSS software (version 25.0; SPSS, Inc., Armonk, NY, USA). Multiple groups were compared using the Welch ANOVA followed by Tukey HSD or Games-Howell post-hoc test. For all analyses, results were considered statistically significant at p < 0.05.

The investigational protocol was approved by the Kanazawa University Advanced Science Research Centre (Approval Number: AP-194052), and all animals were treated in accordance with Kanazawa University Animal Experimentation Regulations. The study was carried out in compliance with the ARRIVE guidelines.

Visit link:
Combined adipose-derived mesenchymal stem cell and antibiotic ... - Nature.com

Global Cell Dissociation Solution Market to Reach USD 872.8 Million by 2030; Increasing R&D Activites in Emerg – openPR

The global cell dissociation solution market is expected to exhibit strong growth, reaching USD 872.8 million by 2030. As per the report titled "Cell dissociation solution Market Size, Share & COVID-19 Impact Analysis, By Type (Tissue Dissociation and Cell Detachment), By Product (Enzymatic Dissociation Products (Collagenase, Trypsin, Papain, Elastase, DNase, Hyaluronidase and Other Enzymes), Non-Enzymatic Dissociation Products and Instruments), By Tissue (Connective Tissues, Epithelial Tissues and Other Type Tissues (Skeletal and Muscles Tissues)), By End User (Pharmaceutical and Biotechnology Companies, Research and Academics and Other End Users), and Regional Forecasts, 2023-2030" observes that the market size in 2022 stood at USD 294.9 million and USD 872.8 million in 2030. The market is expected to exhibit a CAGR of 14.90% during the forecast period.

Get Free Sample @ https://marketsnresearch.com/sample/1660

Symphogen (Denmark) And Thermo Fisher Scientific Collaborated To Further Their Strategic Partnership

In 2020, to improve the discovery and development of biopharmaceuticals, Thermo Fisher Scientific extended its strategic partnership with Symphogen (Denmark). QIAGEN N.V. (Germany) was purchased by Thermo Fisher Scientific in order to increase the scope of its specialty diagnostics offering.

Increasing R&D Activites in Emerging Economies to Accelerate Market Growth

Players in the cell dissociation solutions market can expect to find significant growth prospects in emerging markets like China, India, and Brazil. The number of R&D initiatives in the life sciences sector has increased in these nations. For instance, Indian-based pharmaceutical companies are spending a lot of money on research and development to bring new medicines to market. An Indian pharmaceutical company named Cadila Healthcare Ltd. invested USD 113 million (or 13% more) in R&D in 2020 than it did in 2019. Similar to Biocon, another pharmaceutical business with headquarters in India, spent USD 58.79 million on R&D in 2020, a 52% increase from 2019. The country's demand for items involving cell dissociation solution is predicted to rise as a result of these investments.

Ethical Issues With Cell Biology Research To Constrain Business Expansion

Animals and humans must be employed in cell biology research because stem cell therapies and gene therapy studies that use gene recombination use both animal and human cells. In vivo drug toxicity and pharmacokinetic testing also uses these human and animal cells. This is due to the fact that direct testing on people or animals could be dangerous or even lethal. Furthermore, human embryos are often destroyed in stem cell research trials that employ them for medicinal purposes. In a number of nations around the world, strong restrictions have been developed by ethical authorities to regulate these operations. Cell biology research is being significantly constrained in many different countries due to these ethical issues and limitations on the use of cells for study.

Read More @ https://marketsnresearch.com/report/1660/global-cell-dissociation-solution-market

Major Players Develop Acquisition Plans to Boost Brand Image

The leading businesses in the cell dissociation solution market plan acquisitions to improve their brand recognition globally. For instance, in 2021, a definitive merger agreement between Roche Diagnostics and GenMark Diagnostics was signed in order to have access to cutting-edge technologies for testing several infections in a single patient sample.

Recent Development:In September 2022, Thermo Fisher unveiled the Orbitrap Ascend TriBrid last month at the International Mass Spectrometry Conference in Maastricht, Netherlands. This premium equipment is intended for proteomic and biopharma applications.List of Key Players Profiled in the ReportBDThermo Fisher Scientific Inc.F. Hoffmann-La Roche LtdGE HealthcareMerck KgaAATCCREPROCELL Inc.ALSTEMCellSystemsBIOCOM AGBiological Industries USA, Inc.PelobiotechBrainBits, LLCLabochemaHimedia LaboratoriesBIOCOMPAREPAN-BiotechGemini Bio-ProductsMiltenyi BiotecSTEMCELL Technologies, Inc.Cyagen Biosciences, Inc.PromoCell GmbHIrvine ScientificSigma-Aldrich Co. LLCOthers

Read More News

https://www.linkedin.com/pulse/cell-dissociation-solution-market-reach-usd-8728-million-vasa/?published=thttps://demo.sngine.com/blogs/183774/Cell-Dissociation-Solution-Market-Size-Type-Share-Demand-Drives-Growthhttps://www.benedeek.com/blogs/39503/Cell-Dissociation-Solution-Market-New-Investment-Growth-Opportunities-and-Analysishttps://www.gift-me.net/blogs/23581/Cell-Dissociation-Solution-Market-Global-Snapshot-Analysis-and-Growth-Opportunitieshttps://connect.rhabits.io/blogs/222292/Cell-Dissociation-Solution-Market-Analysis-Growth-Trends-Opportunities-and-Developmenthttps://www.nasseej.net/blogs/26106/Cell-Dissociation-Solution-Market-Size-Share-Top-Trends-Growth-andhttp://wwfanclub.com/blogs/179415/Cell-Dissociation-Solution-Market-Statistics-Segment-Trends-Size-Share-Typehttps://www.login.ps/blogs/25088/Cell-Dissociation-Solution-Market-to-Witness-an-Outstanding-Growth-byhttps://www.tamaiaz.com/blogs/32828/Cell-Dissociation-Solution-Market-Estimated-to-Flourish-at-by-2030https://heroes.app/blogs/225743/Cell-Dissociation-Solution-Market-Set-to-Witness-an-Uptick-duringhttps://www.exoltech.net/blogs/48740/Cell-Dissociation-Solution-Market-foreseen-to-grow-exponentially-over-2030https://gemawiraclub.com/blogs/7373/Cell-Dissociation-Solution-Market-Estimated-to-Experience-a-Hike-inhttps://social.studentb.eu/read-blog/72962https://kyourc.com/read-blog/63748https://yruz.one/blogs/18074/Cell-Dissociation-Solution-Market-Size-Share-Top-Trends-Growth-andhttps://moniispace.com/read-blog/21427http://eteria.net/read-blog/22390https://hissme.com/read-blog/52258https://blue.et/create-blog/#https://cryptofriender.com/read-blog/3136https://www.vkay.net/read-blog/3758https://socialblast.club/read-blog/3046https://legalledger.in/read-blog/12540https://talkin.co.ke/read-blog/5327https://baitk.com/read-blog/6101https://www.pickmemo.com/read-blog/130043https://stompster.com/read-blog/106510https://snapside.com/read-blog/699https://makenix.com/read-blog/20981https://ourclass.mn.co/posts/cell-dissociation-solution-market-revenue-growth-opportunities-and-dynamic-business-by-2030https://synkretic.mn.co/posts/cell-dissociation-solution-market-analytical-overview-and-sizevalue-and-volume-by-2030https://wecanchat.mn.co/posts/cell-dissociation-solution-market-growth-development-and-challenges-with-forecast-2030https://beranda.mn.co/posts/cell-dissociation-solution-market-key-futuristic-top-trends-and-competitive-landscape-by-2030https://janjaonline.mn.co/posts/cell-dissociation-solution-market-trends-and-dynamic-2030https://stemfemmes.mn.co/posts/cell-dissociation-solution-market-predicted-to-accelerate-the-growth-by-2023-2030https://markettrendsdotin.wordpress.com/2023/03/03/cell-dissociation-solution-market-global-forecasts-upto2023-2030/https://medium.com/@sandra_85356/cell-dissociation-solution-market-recent-trends-development-growth-and-forecast-2023-2030-29b6031825c2https://rentry.co/srwxmhttps://www.homify.co.uk/ideabooks/9286674/cell-dissociation-solution-market-detailed-analysis-and-forecast-2023-2030https://www.vingle.net/posts/5431951https://justpaste.it/37ogqhttps://pastelink.net/v7jnzgj4https://www.evernote.com/shard/s410/sh/37788eb2-85c0-5995-3cee-eee3c332b9e4/rYdOdclTzKvg5MP0un7lmISPj4nd-cDXaG5nexvwKkgJQrqT0TCjZCBY3Ahttps://onmogul.com/stories/cell-dissociation-solution-market-overview-and-regional-outlook-study-2023-2030https://www.findit.com/imhuropllouacvm/RightNow/cell-dissociation-solution-market-dynamic-business2/9d9230ab-5ed6-453a-99cc-f948c34c1f59https://markettrends.hashnode.dev/cell-dissociation-solution-market-to-witness-an-astonishing-growth-by-2030https://www.reddit.com/user/Material-World6244/comments/11gzvjm/cell_dissociation_solution_market_current_trends/https://gab.com/sandrak1/posts/109959418465430489https://uberant.com/article/1902666-cell-dissociation-solution-market-share-and-growth-factors-impact-analysis-2023-2030/https://www.diigo.com/item/note/9wuh3/m3dj?k=b6074282955eb51d792796e3cd7efcc4https://writeablog.net/cnmzpdk6kehttps://posteezy.com/cell-dissociation-solution-market-projected-witness-double-digit-cagr-during-2030http://prsync.com/markets-n-research/cell-dissociation-solution-market-to-witness-growth-acceleration-during--3702657/https://www.zupyak.com/p/3528065/t/cell-dissociation-solution-market-projected-to-be-resilient-during-2030https://www.xing.com/discover/detail-activities/6725664026.8d0e87?trackingTokens=disco.module.me-feed%3A584208bcb9c211ed80ed9a552be7ad33%3A0.6725664026.activities_activityhttps://blogfreely.net/sandrak1/cell-dissociation-solution-market-projected-to-witness-vigorous-expansion-byhttps://www.instapaper.com/read/1584858629https://www.pearltrees.com/sandrak1/item504304194https://www.bookmarkrush.com/submit-story/https://bookmarkfrog.com/submit-story/https://www.bookmarkrocket.com/submit-story/https://www.bookmarkmonk.com/submit-story/https://www.bookmarkmonk.com/story/cell-dissociation-solution-market-top-trends-present-history-future-and-forecast-2030/https://www.bookmarkrush.com/story/cell-dissociation-solution-market-poised-to-garner-maximum-revenues-during-2030/https://bookmarkfrog.com/story/cell-dissociation-solution-market-expansion-projected-to-gain-an-uptick-during-2030/https://www.bookmarkrocket.com/story/cell-dissociation-solution-market-newer-segments-of-application-2030/https://omiyou.com/read-blog/22132https://famenest.com/read-blog/26765https://network-1062788.mn.co/posts/33235761https://ubiz.chat/read-blog/39298https://vherso.com/read-blog/36958https://www.dr-ay.com/blogs/56741/Cell-Dissociation-Solution-Market-Current-Outlook-Of-Industry-Forecast-2023

Markets N Research1016 W Jackson Blvd Chicago, IL 60607 United StatesTel: +17736491529Email: sales@marketsnresearch.com

Markets N Research team is comprised of well skilled and equipped personnel ready to concur any upcoming challenges in the market sector for both individual people and organization around the world. We know time is money, and therefore we ensure we solve your problem within the shortest time possible to prevent delays or missing any opportunities. We use globally accepted techniques with a little innovation from our staff in solving all your market research related challenges.

This release was published on openPR.

Link:
Global Cell Dissociation Solution Market to Reach USD 872.8 Million by 2030; Increasing R&D Activites in Emerg - openPR

Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights – Yahoo Finance

Homology Medicines, Inc.

- On Track to Provide Initial Clinical Data from Gene Editing Trial for PKU Mid-Yearwith First Participant Dosed and Others in Screening -

- Initial Clinical Data from Gene Therapy Trial for Hunter Syndrome Anticipatedin Second Half of 2023; Trial Recruiting in the U.S. and Canada -

- Anticipated Cash Runway Into Fourth Quarter 2024 Enables Execution Against Key Milestones -

BEDFORD, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent accomplishments.

We entered 2023 with strong momentum across our gene editing and gene therapy clinical trials for PKU and Hunter syndrome, and we anticipate initial data read-outs from both programs this year, said Albert Seymour, Ph.D., President and Chief Executive Officer of Homology Medicines. Dosing of the first patient in the pheEDIT trial for PKU marked a key milestone for Homology, and the forthcoming data will represent the first gene editing data in PKU patients. We believe the continued interest in the juMPStart trial for Hunter syndrome underscores the impact a one-time gene therapy with potential to address both the peripheral and CNS disease manifestations could have for patients and their loved ones.

Continued Dr. Seymour, We recently shared a series of data that support these programs, including preclinical work on the targeted immunosuppression regimen being utilized in both pheEDIT and juMPStart. We also unveiled details of our optimized MLD gene therapy candidate, demonstrating its ability to cross the blood-brain-barrier in the disease model with enzyme activity expected to lead to in vivo efficacy. The third arm of our platform, GTx-mAb, continues to advance as we move HMI-104 for PNH through IND-enabling studies. We are well-positioned to execute against key milestones with anticipated funding into the fourth quarter of 2024.

Story continues

Fourth Quarter 2022 and Recent Accomplishments

Dosed first participant in the Phase 1 pheEDIT clinical trial evaluating in vivo nuclease-free gene editing candidate HMI-103 in adults with phenylketonuria (PKU); additional participants are in screening. Homology continues to expect initial clinical data from the trial mid-year 2023.

Shared preclinical data that showed murine surrogate of HMI-103 was ten times more potent than non-integrating gene therapy vector HMI-102 in the murine model of PKU; HMI-103 is designed with a unique mechanism of action (MOA) to maximize PAH enzyme through both genome integration and episomal expression, and it has the potential to treat adults and pediatric patients.

Building on physician and patient interest, anticipate initial clinical data from the HMI-203 juMPStart gene therapy trial for Hunter syndrome in the second half of 2023.

Presented data that support the targeted immunosuppressive regimen in Homologys clinical trials. In non-human primates (NHPs), the combination of a T-cell inhibitor and steroid was most effective in reducing the immune response to AAVHSC and improving gene expression.

Presented preclinical data with HMI-204, Homologys optimized, in vivo gene therapy candidate for metachromatic leukodystrophy (MLD). A single I.V. dose in the murine model of MLD led to robust expression in the central nervous system (CNS), including sustained levels of enzyme activity reaching levels of normal human adults and predicted to lead to efficacy in vivo. Homology continues to seek a partner for the optimized product candidate, which is ready to enter IND-enabling studies.

Progressed HMI-104, a C5 monoclonal antibody (mAb) development candidate for paroxysmal nocturnal hemoglobinuria (PNH), through IND-enabling studies. HMI-104 is the first candidate that utilizes the Companys GTx-mAb platform and is focused on using the liver to express a C5 mAb with a one-time dose. Homology believes its GTx-mAb platform has the potential to address larger market indications.

Announced today thepromotion of Julie Jordan, M.D., to Chief Medical Officer.

Fourth Quarter 2022 and Full Year Financial Results

Net loss for the quarter ended December 31, 2022 was $(34.3) million or $(0.60) per share, compared to a net loss of $(33.6) million or $(0.59) per share for the same period in 2021. Net loss for the year ended December 31, 2022 was $(5.0) million or $(0.09) per share, compared to a net loss of $(95.8) million or $(1.73) per share for the same period in 2021. The decrease in net loss was primarily due to a gain of $131.2 million realized in connection with the Companys sale of its manufacturing business to Oxford Biomedica in order to establish Oxford Biomedica Solutions (OXB Solutions), an AAV Innovation and Manufacturing Business, in the first quarter of 2022, partially offset by lower collaboration revenues in 2022.

Collaboration revenues for the three and twelve months ended December 31, 2022 were $0.8 million and $3.2 million, respectively, as compared to $0.8 million and $34.0 million for the comparable periods in 2021. Collaboration revenues in 2022 consisted of revenue recognized under the Companys stock purchase agreement with Pfizer compared with collaboration revenues in 2021, which were primarily the result of concluding the Companys collaboration with Novartis.

Total operating expenses for the three and twelve months ended December 31, 2022 were $35.3 million and $136.5 million, respectively, as compared to $34.4 million and $129.9 million for the comparable periods in 2021, and consisted of research and development expenses and general and administrative expenses.

Research and development expenses for the three and twelve months ended December 31, 2022 were $27.2 million and $98.4 million, respectively, as compared to $23.6 million and $93.1 million for the comparable periods in 2021. Research and development expenses increased by $5.3 million in 2022 primarily due to increases in direct costs of $9.3 million related to pheEDIT and $3.9 million related to juMPStart, as we incurred costs to initiate sites and recruit patients. Additionally, there was a $5.8 million increase in direct research expenses related to our other development-stage programs, primarily due to higher spending on HMI-104. Partially offsetting these increases was a $15.6 million decrease in employee-related costs as a result of transferring employees to OXB Solutions in order to leverage the Companys in-house manufacturing capabilities while establishing a 20% ownership stake and preferred customer status in the new business.

General and administrative expenses for the three and twelve months ended December 31, 2022 were $8.1 million and $38.1 million, respectively, as compared to $10.8 million and $36.8 million for the comparable periods in 2021. General and administrative expenses increased in 2022 due primarily to professional fees associated with the establishment of OXB Solutions.

As of December 31, 2022, Homology had approximately $175.0 million in cash, cash equivalents and short-term investments. Based on current projections, Homology expects current cash resources to fund operations into the fourth quarter of 2024.

Upcoming Events

About Homology Medicines, Inc.Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Companys clinical programs include HMI-103, a gene editing candidate for phenylketonuria (PKU); HMI-203, an investigational gene therapy for Hunter syndrome; and HMI-102, an investigational gene therapy for adults with PKU. Additional programs focus on paroxysmal nocturnal hemoglobinuria (PNH), metachromatic leukodystrophy (MLD) and other diseases. Homologys proprietary platform is designed to utilize its family of 15 human hematopoietic stem cell-derived adeno-associated virus (AAVHSCs) vectors to precisely and efficiently deliver genetic medicines in vivo through a nuclease-free gene editing modality, gene therapy, or GTx-mAb, which is designed to produce antibodies throughout the body. Homology established an AAV manufacturing and innovation business in partnership with Oxford Biomedica, which was based on Homologys internal process development and manufacturing platform. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a focus on rare diseases. Homology believes its initial clinical data and compelling preclinical data, scientific and product development expertise and broad intellectual property position the Company as a leader in genetic medicines. For more information, visit http://www.homologymedicines.com.

Forward-Looking Statements This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: our plans to engage in future collaborations and strategic partnerships; our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; the potential of our gene therapy and gene editing platforms, including our GTx-mAb platform; our plans and timing for the release of additional preclinical and clinical data; our plans to progress our pipeline of genetic medicine candidates and the anticipated timing for these milestones; our position as a leader in the development of genetic medicines; the sufficiency of our cash and cash equivalents to fund our operations; and our participation in upcoming presentations and conferences. The words believe, may, will, estimate, potential, continue, anticipate, intend, expect, could, would, project, plan, target, and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of the COVID-19 pandemic and general economic conditions on our business and operations, including our preclinical studies and clinical trials; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property; and significant costs incurred as a result of operating as a public company. These and other important factors discussed under the caption Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

- Financial Tables Follow -

HOMOLOGY MEDICINES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

December31,

2022

2021

Cash, cash equivalents and short-term investments

$

175,026

$

155,873

Assets held for sale

28,907

Equity method investment

25,814

Property and equipment, net

1,078

2,252

Right-of-use assets

20,563

15,607

Other assets

5,989

9,082

Total assets

$

228,470

Read the original post:
Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights - Yahoo Finance

Development of an immune-related gene prognostic risk model and … – BMC Gastroenterology

Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi DJ, John A, Lim YC, Kibria KMK, Mohiuddin AKM, Ming LC, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers. 2022;14(7):1732.

Article PubMed PubMed Central Google Scholar

Jia S-N, Han Y-B, Yang R, Yang Z-C. Chemokines in colon cancer progression. Semin Cancer Biol. 2022;86(Pt 3):4007.

Article CAS PubMed Google Scholar

Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. Gastroenterology. 2020;158(2):41832.

Article CAS PubMed Google Scholar

Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479516.

Article CAS PubMed Google Scholar

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):32959.

Article PubMed Google Scholar

Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:3128.

Article CAS PubMed Google Scholar

Kather JN, Halama N, Jaeger D. Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Semin Cancer Biol. 2018;52(Pt 2):18997.

Article CAS PubMed Google Scholar

Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45(10):111320.

Article PubMed PubMed Central Google Scholar

Shankar RD, Bhattacharya S, Jujjavarapu C, Andorf S, Wiser JA, Butte AJ. RImmPort: an R/bioconductor package that enables ready-for-analysis immunology research data. Bioinformatics. 2017;33(7):11013.

Article CAS PubMed Google Scholar

Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, Hu Z, Zalocusky KA, Shankar RD, Shen-Orr SS, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5: 180015.

Article CAS PubMed PubMed Central Google Scholar

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e10810.

Article CAS PubMed PubMed Central Google Scholar

Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, Shin H, Wong SS, Ma J, Lei Y, et al. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011;12(8):R83.

Article CAS PubMed PubMed Central Google Scholar

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498504.

Article CAS PubMed PubMed Central Google Scholar

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):20949.

Article PubMed Google Scholar

Wang Y, Zhang X, Dai X, He D. Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma. Expert Rev Anticancer Ther. 2021;21(10):116170.

Article CAS PubMed Google Scholar

He W, Wang B, He J, Zhao Y, Zhao W. SSR4 as a prognostic biomarker and related with immune infiltration cells in colon adenocarcinoma. Expert Rev Mol Diagn. 2022;22(2):22331.

Article CAS PubMed Google Scholar

Duan L, Yang W, Wang X, Zhou W, Zhang Y, Liu J, Zhang H, Zhao Q, Hong L, Fan D. Advances in prognostic markers for colorectal cancer. Expert Rev Mol Diagn. 2019;19(4):31324.

Article CAS PubMed Google Scholar

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):54150.

Article CAS PubMed PubMed Central Google Scholar

Plundrich D, Chikhladze S, Fichtner-Feigl S, Feuerstein R, Briquez PS. Molecular mechanisms of tumor immunomodulation in the microenvironment of colorectal cancer. Int J Mol Sci. 2022;23(5):2782.

Article CAS PubMed PubMed Central Google Scholar

Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):55972.

Article CAS PubMed PubMed Central Google Scholar

Frigerio S, Lartey DA, DHaens GR, Grootjans J. The role of the immune system in IBD-associated colorectal cancer: from pro to anti-tumorigenic mechanisms. Int J Mol Sci. 2021;22(23):12739.

Article CAS PubMed PubMed Central Google Scholar

Jin K, Ren C, Liu Y, Lan H, Wang Z. An update on colorectal cancer microenvironment, epigenetic and immunotherapy. Int Immunopharmacol. 2020;89(Pt A): 107041.

Article CAS PubMed Google Scholar

Umansky V, Blattner C, Fleming V, Hu X, Gebhardt C, Altevogt P, Utikal J. Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol. 2017;39(3):295305.

Article CAS PubMed Google Scholar

Garrido F, Perea F, Bernal M, Sanchez-Palencia A, Aptsiauri N, Ruiz-Cabello F. The escape of cancer from T cell-mediated immune surveillance: HLA class I loss and tumor tissue architecture. Vaccines (Basel). 2017;5(1):7.

Article PubMed Google Scholar

Dumauthioz N, Labiano S, Romero P. Tumor resident memory T cells: new players in immune surveillance and therapy. Front Immunol. 2018;9:2076.

Article PubMed PubMed Central Google Scholar

Pags F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):212839.

Article PubMed Google Scholar

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, Lafontaine L, Fischer M, Fredriksen T, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44(3):698711.

Article CAS PubMed Google Scholar

Tang YQ, Chen TF, Zhang Y, Zhao XC, Zhang YZ, Wang GQ, Huang ML, Cai SL, Zhao J, Wei B, et al. The tumor immune microenvironment transcriptomic subtypes of colorectal cancer for prognosis and development of precise immunotherapy. Gastroenterol Rep (Oxf). 2020;8(5):3819.

Article PubMed Google Scholar

Qie D, Zhang Y, Gong X, He Y, Qiao L, Lu G, Li Y. SLC10A2 deficiency-induced congenital chronic bile acid diarrhea and stunting. Mol Genet Genomic Med. 2021;9(8): e1740.

Article CAS PubMed PubMed Central Google Scholar

Raufman JP, Dawson PA, Rao A, Drachenberg CB, Heath J, Shang AC, Hu S, Zhan M, Polli JE, Cheng K. Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis. 2015;36(10):1193200.

Article CAS PubMed PubMed Central Google Scholar

Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O, Lengyel E. Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Res. 2020;80(8):174861.

Article CAS PubMed Google Scholar

Ji L, Qian W, Gui L, Ji Z, Yin P, Lin GN, Wang Y, Ma B, Gao WQ. Blockade of beta-catenin-induced CCL28 suppresses gastric cancer progression via inhibition of Treg cell infiltration. Cancer Res. 2020;80(10):200416.

Article CAS PubMed Google Scholar

Zhu C, Sun Z, Li C, Guo R, Li L, Jin L, Wan R, Li S. Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2. Cell Signal. 2014;26(5):112534.

Article CAS PubMed Google Scholar

Teng Y, Guo B, Mu X, Liu S. KIF26B promotes cell proliferation and migration through the FGF2/ERK signaling pathway in breast cancer. Biomed Pharmacother. 2018;108:76673.

Article CAS PubMed Google Scholar

Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41-52.

Article PubMed PubMed Central Google Scholar

Teng G, Papavasiliou FN. Immunoglobulin somatic hypermutation. Annu Rev Genet. 2007;41:10720.

Article CAS PubMed Google Scholar

Pan KF, Lee WJ, Chou CC, Yang YC, Chang YC, Chien MH, Hsiao M, Hua KT. Direct interaction of beta-catenin with nuclear ESM1 supports stemness of metastatic prostate cancer. EMBO J. 2021;40(4): e105450.

Article CAS PubMed Google Scholar

Giulianelli R, Nardoni S, Bruzzese D, Falavolti C, Mirabile G, Bellangino M, Tema G, Gentile BC, Albanesi L, Buscarini M, et al. Urotensin II receptor expression in prostate cancer patients: a new possible marker. Prostate. 2019;79(3):28894.

Article CAS PubMed Google Scholar

Hirayasu Y, Oya M, Okuyama T, Kiumi F, Ueda Y. Vasoactive intestinal peptide and its relationship to tumor stage in colorectal carcinoma: an immunohistochemical study. J Gastroenterol. 2002;37:33644.

Article PubMed Google Scholar

Fernandez-Martinez AB, Bajo AM, Sanchez-Chapado M, Prieto JC, Carmena MJ. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Prostate. 2009;69(7):77486.

Article CAS PubMed Google Scholar

Hara M, Takeba Y, Iiri T, Ohta Y, Ootaki M, Watanabe M, Watanabe D, Koizumi S, Otsubo T, Matsumoto N. Vasoactive intestinal peptide increases apoptosis of hepatocellular carcinoma by inhibiting the cAMP/Bcl-xL pathway. Cancer Sci. 2019;110(1):23544.

Article CAS PubMed Google Scholar

Wen S, He L, Zhong Z, Mi H, Liu F. Prognostic model of colorectal cancer constructed by eight immune-related genes. Front Mol Biosci. 2020;7: 604252.

Article CAS PubMed PubMed Central Google Scholar

Shani O, Vorobyov T, Monteran L, Lavie D, Cohen N, Raz Y, Tsarfaty G, Avivi C, Barshack I, Erez N. Fibroblast-derived IL33 facilitates breast cancer metastasis by modifying the immune microenvironment and driving type 2 immunity. Cancer Res. 2020;80(23):531729.

Article CAS PubMed PubMed Central Google Scholar

Wu R, Li K, Yuan M, Luo KQ. Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells. Oncogene. 2021;40(12):216581.

Article CAS PubMed Google Scholar

Parsi S, Soltani BM, Hosseini E, Tousi SE, Mowla SJ. Experimental verification of a predicted intronic microRNA in human NGFR gene with a potential pro-apoptotic function. PLoS ONE. 2012;7(4): e35561.

Article CAS PubMed PubMed Central Google Scholar

Sobrero AF, Puccini A, Shi Q, Grothey A, Andre T, Shields AF, Souglakos I, Yoshino T, Iveson T, Ceppi M, et al. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur J Cancer. 2020;138:1828.

Article CAS PubMed Google Scholar

Qaderi SM, Dickman PW, de Wilt JHW, Verhoeven RHA. Conditional survival and cure of patients with colon or rectal cancer: a population-based study. J Natl Compr Canc Netw. 2020;18(9):12307.

Article PubMed Google Scholar

Li Q, Cai G, Li D, Wang Y, Zhuo C, Cai S. Better long-term survival in young patients with non-metastatic colorectal cancer after surgery, an analysis of 69,835 patients in SEER database. PLoS ONE. 2014;9(4): e93756.

Article PubMed PubMed Central Google Scholar

Weinberg BA, Marshall JL. Colon cancer in young adults: trends and their implications. Curr Oncol Rep. 2019;21(1):3.

Article PubMed Google Scholar

Vinuesa AG, Sancho R, Garcia-Limones C, Behrens A, ten Dijke P, Calzado MA, Munoz E. Vanilloid receptor-1 regulates neurogenic inflammation in colon and protects mice from colon cancer. Cancer Res. 2012;72(7):170516.

Article CAS PubMed Google Scholar

Read this article:
Development of an immune-related gene prognostic risk model and ... - BMC Gastroenterology

Growth changes of tomato seedlings responding to sodium salt of … – Nature.com

Gebrehiwot, A. A. et al. Using ABM to study the potential of land use change for mitigation of food deserts. Sustainability 14(15), 9715. https://doi.org/10.3390/su14159715 (2022).

Article Google Scholar

Verma, B., Pramanik, P., & Bhaduri, D. Organic fertilizers for sustainable soil and environmental management. in Nutrient Dynamics for Sustainable Crop Production (Meena, R.S. Ed.). 289313 (Springer, 2020).

Droste, N. et al. Soil carbon insures arable crop production against increasing adverse weather due to climate change. Environ. Res. Lett. https://doi.org/10.1088/1748-9326/abc5e3 (2020).

Article Google Scholar

Daba, N. et al. Long-term fertilization and lime-induced soil pH changes affect nitrogen use efficiency and grain yields in acidic soil under wheat-maize rotation. Agronomy 11, 2069. https://doi.org/10.3390/agronomy11102069 (2021).

Article CAS Google Scholar

Yan, L. et al. Spatiotemporal distribution of chemical fertilizer application and manure application potential in China. Environ. Eng. Sci. 36, 13371348. https://doi.org/10.1089/ees.2018.0486 (2019).

Article CAS Google Scholar

Gang-Hua, L. I. High quality and high efficiency fertilization of rice. J. Integr. Agric. 20, 14351437. https://doi.org/10.1016/S2095-3119(21)63683-3 (2021).

Article Google Scholar

Warsame, A. A., Mohamed, J. & Mohamed, A. A. The relationship between environmental degradation, agricultural crops, and livestock production in somalia. Environ. Sci. Pollut. Res. Int. 30(3), 78257835. https://doi.org/10.1007/s11356-022-22595-8 (2023).

Article PubMed Google Scholar

Wu, J. et al. More land, less pollution? How land transfer affects fertilizer application. Int. J. Environ. Res. Public Health 18, 11268. https://doi.org/10.3390/ijerph182111268 (2021).

Article PubMed PubMed Central Google Scholar

Ye, L. et al. Bio-organic fertilizer with reduced rates of chemical fertilization improves soil fertility and enhances tomato yield and quality. Sci. Rep.-UK 10, 1. https://doi.org/10.1038/s41598-019-56954-2 (2020).

Article CAS Google Scholar

Li, X. Decision-making behavior of fertilizer application of grain growers in Heilongjiang Province from the perspective of risk preference and risk perception. Math. Probl. Eng. https://doi.org/10.1155/2021/6667558 (2021).

Article Google Scholar

Stuart, A. M. et al. Yield gaps in rice-based farming systems: Insights from local studies and prospects for future analysis. Field Crops Res. 194, 4356. https://doi.org/10.1016/j.fcr.2016.04.039 (2016).

Article Google Scholar

Yueyue, T. et al. Effects of plant growth regulators on flower abscission and growth of tea plant Camellia sinensis (L.) O. Kuntze. J. Plant Growth Regul. 41(3), 11611173. https://doi.org/10.1007/s00344-021-10365-8 (2022).

Article CAS Google Scholar

Liu, C. et al. Novel plant growth regulator guvermectin from plant growth-promoting rhizobacteria boosts biomass and grain yield in rice. J. Agricult. Food Chem. 70(51), 1622916240. https://doi.org/10.1021/acs.jafc.2c07072 (2022).

Article CAS Google Scholar

Widyastuti, T. The paclobutrazol application and pinching technique on lisianthus plants. Earth Environ. Sci. 752, 1. https://doi.org/10.1088/1755-1315/752/1/012055 (2021).

Article Google Scholar

Hajihashemi, S. Physiological, biochemical, antioxidant and growth characterizations of gibberellin and paclobutrazol-treated sweet leaf herb. J. Plant Biochem. Biotechnol. 27(2), 237240. https://doi.org/10.1007/s13562-017-0428-4 (2018).

Article MathSciNet CAS Google Scholar

Khan, N., Bano, A. & Babar, M. D. A. Impacts of plant growth promoters and plant growth regulators on rainfed agriculture. PLoS ONE 15(4), 1. https://doi.org/10.1371/journal.pone.0231426 (2020).

Article CAS Google Scholar

Bhalla, K., Singh, S. B. & Agarwal, R. Quantitative determination of gibberellins by high performance liquid chromatography from various gibberellins producing fusarium strains. Environ. Monit. Assess. 167(14), 515520. https://doi.org/10.1007/s10661-009-1068-5 (2010).

Article CAS PubMed Google Scholar

Dos Santos, J. A. et al. Morphophysiological changes by mepiquat chloride application in eucalyptus clones. Trees 35(1), 189198. https://doi.org/10.1007/s00468-020-02021-7 (2021).

Article CAS Google Scholar

Arampatzis, D. A., Karkanis, A. C. & Tsiropoulos, N. G. Impact of plant density and mepiquat chloride on growth, yield, and silymarin content of Silybum marianum grown under Mediterranean semi-arid conditions. Agronomy 9(11), 669. https://doi.org/10.3390/agronomy9110669 (2019).

Article CAS Google Scholar

Anastassiadou, M. et al. Modification of the temporary maximum residue level for mepiquat in oyster mushrooms. EFSA J. 17, 7. https://doi.org/10.2903/j.efsa.2019.5744 (2019).

Article Google Scholar

Dalimunthe, R. H., Setiado, H., Lubis, K. & Damanik, R. I. Effect of paclobutrazol in micro tuberization of potato cultivar Granola Kembang and Repita (IOP Conference Series) (Earth and Environmental Science, 2021). https://doi.org/10.1088/1755-1315/782/4/042058.

Book Google Scholar

Bao, W. et al. A single gene transfer of gibberellin biosynthesis gene cluster increases gibberellin production in a Fusarium fujikuroi strain with gibberellin low producibility. Plant Pathol. 69(5), 901910. https://doi.org/10.1111/ppa.13176 (2020).

Article CAS Google Scholar

Le, V. N. et al. The potential health risks and environmental pollution associated with the application of plant growth regulators in vegetable production in several suburban areas of Hanoi, Vietnam. Biol. Futura 71(3), 323331. https://doi.org/10.1007/s42977-020-00041-5 (2020).

Article CAS Google Scholar

Ricci, M., Tilbury, L., Daridon, B. & Sukalac, K. General principles to justify plant biostimulant claims. Front. Plant Sci. 10, 494. https://doi.org/10.3389/fpls.2019.00494 (2019).

Article PubMed PubMed Central Google Scholar

Essawy, H. A. et al. Potassium fulvate-functionalized graft copolymer of polyacrylic acid from cellulose as a promising selective chelating sorben. RSC Adv. 7, 2017820185. https://doi.org/10.1039/C7RA02646C (2017).

Article ADS CAS Google Scholar

Canellas, L. P. et al. Humic and fulvic acids as biostimulants in horticultureA review. Sci. Hortic. 196, 1527. https://doi.org/10.1016/j.scienta.2015.09.013 (2013).

Article CAS Google Scholar

Ghazy, M. et al. Potassium fulvate as co-interpenetrating agent during graft polymerization of acrylic acid from cellulose. Int. J. Biol. Macromol. https://doi.org/10.1016/j.ijbiomac.2016.06.088 (2016).

Article PubMed Google Scholar

Elrys, A. S. et al. Integrative application of licorice root extract or lipoic acid with fulvic acid improves wheat production and defenses under salt stress conditions. Ecotoxicol. Environ. Saf. 190, 110144. https://doi.org/10.1016/j.ecoenv.2019.110144 (2020).

Article CAS PubMed Google Scholar

Cayn Salinas, D. G. et al. Application of naphthalene acetic acid and gibberellic acid favours fruit induction and development in oil palm hybrid (Elaeis oleifera x Elaeis guineensis). Exp. Agric. https://doi.org/10.1017/S001447972200031X (2022).

Article Google Scholar

Ahmad, A. S., Abramov, A. G., Shalamova, A. A. & Antar, M. B. Effect of humic acid and naphthalene acetic acid on vegetative growth and fruit quality of tomato plants lycopersicon esculentum. Vestnik Rossijskogo Univ. Druby Narodov 15(1), 3039. https://doi.org/10.22363/2312-797X-2020-15-1-30-39 (2020).

Article Google Scholar

Xing, X. et al. Improved drought tolerance by -naphthaleneacetic acid-induced ROS accumulation in two soybean cultivars. J. Integr. Agric. https://doi.org/10.1016/S2095-3119(15)61273-4 (2016).

Article Google Scholar

Yang, F. et al. Plant growth regulation enhanced potassium uptake and use efficiency in cotton. Field Crops Res. 163, 109118. https://doi.org/10.1016/j.fcr.2014.03.016 (2014).

Article Google Scholar

Zhang, H. J., Zhang, H. Y. & Yu, J. H. Effects of -naphthalene acetic acid sodium on yield and endogenous hormones of greenhouse grown pepper in desert area. J. Desert Res. 33, 13901399 (2013).

Google Scholar

Ali, M., Mujib, A., Zafar, N. & Tonk, D. Somatic embryogenesis, biochemical alterations and synthetic seed development in two varieties of coriander (Coriandrum sativum L.). Adv. Hortic. Sci. 32(2), 239248. https://doi.org/10.13128/ahs-22287 (2018).

Article Google Scholar

Hesami, M., Daneshvar, M. H. & Yoosefzadeh-Najafabadi, M. An efficient in vitro shoot regeneration through direct organogenesis from seedling-derived petiole and leaf segments and acclimatization of Ficus religiosa. J. For. Res. 30(3), 807815. https://doi.org/10.1007/s11676-018-0647-0 (2019).

Article CAS Google Scholar

Ren, M. et al. Assessing the genetic improvement in inbred late rice against chilling stress: Consequences for spikelet fertility, pollen viability and anther characteristics. Agronomy 12, 1894. https://doi.org/10.3390/agronomy12081894 (2022).

Article Google Scholar

Rahimi, A., Mohammadi, M. M., Siavash Moghaddam, S., Heydarzadeh, S. & Gitari, H. Effects of stress modifier biostimulants on vegetative growth, nutrients, and antioxidants contents of garden thyme (Thymus vulgaris L.) under water deficit conditions. J. Plant Growth Regul. 41(5), 20592072. https://doi.org/10.1007/s00344-022-10604-6 (2022).

Article CAS Google Scholar

Noh, E., Fallen, B., Payero, J. & Narayanan, S. Parsimonious root systems and better root distribution can improve biomass production and yield of soybean. PLoS ONE https://doi.org/10.1371/journal.pone.0270109 (2022).

Article PubMed PubMed Central Google Scholar

Halpern, M. et al. Chapter two: The use of biostimulants for enhancing nutrient uptake. Adv. Agron. 130, 141174. https://doi.org/10.1016/bs.agron.2014.10.001 (2015).

Article Google Scholar

Liu, L. et al. Direct evidence of drought stress memory in mulberry from a physiological perspective: Antioxidative, osmotic and phytohormonal regulations. Plant Physiol. Biochem. (PPB) 186, 7687. https://doi.org/10.1016/j.plaphy.2022.07.001 (2022).

Article CAS PubMed Google Scholar

Liang, J. et al. Dualistic effects of bisphenol A on growth, photosynthetic and oxidative stress of duckweed (Lemna minor). Environ. Sci. Pollut. Res. Int. 29(58), 8771787729. https://doi.org/10.1007/s11356-022-21785-8 (2022).

Article CAS PubMed Google Scholar

Lixiao, N. et al. Enhancement in seed priming-induced starch degradation of rice seed under chilling stress via GA-mediated -amylase expression. Rice https://doi.org/10.1186/s12284-022-00567-3 (2022).

Article Google Scholar

Gu, K. et al. The physiological response of different tobacco varieties to chilling stress during the vigorous growing period. Sci. Rep. 11(1), 22136. https://doi.org/10.1038/s41598-021-01703-7 (2021).

Article ADS CAS PubMed PubMed Central Google Scholar

Li, F. et al. Application of enzymatic hydrolysate of Ulva clathrata as biostimulant improved physiological and metabolic adaptation to salt-alkaline stress in wheat. J. Appl. Phycol. 34(3), 17791789. https://doi.org/10.1007/s10811-022-02684-4 (2022).

Article CAS Google Scholar

Wang, W. et al. Animal-derived plant biostimulant alleviates drought stress by regulating photosynthesis, osmotic adjustment, and antioxidant systems in tomato plants. Sci. Hortic. https://doi.org/10.1016/j.scienta.2022.111365 (2022).

Article Google Scholar

Chi, Y. et al. Utilization of Durvillaea antarctica (Chamisso) Hariot extract as a biostimulant to enhance the growth of cucumber (Cucumis sativus L.) seedlings. J. Plant Growth Regul. 41(8), 32083217. https://doi.org/10.1007/s00344-021-10506-z (2022).

Article CAS Google Scholar

Duan, R., Ma, Y., & Yang, L. Effects of shading on photosynthetic pigments and photosynthetic parameters of Lespedeza buergeri seedlings. in IOP Conference Series. Materials Science and Engineering Vol. 452(2). https://doi.org/10.1088/1757-899X/452/2/022158 (2018).

Li, J. et al. Seasonal changes of leaf chlorophyll content as a proxy of photosynthetic capacity in winter wheat and paddy rice. Ecol. Indic. https://doi.org/10.1016/j.ecolind.2022.109018 (2022).

Article Google Scholar

Mozhgan, A., Kazemeini, S. A., Mozhgan, S. & Ali, D. Simultaneous application of rhizobium strain and melatonin improves the photosynthetic capacity and induces antioxidant defense system in common bean (Phaseolus vulgaris L.) under salinity stress. J. Plant Growth Regul. 41(3), 13671381. https://doi.org/10.1007/s00344-021-10386-3 (2022).

Article CAS Google Scholar

Sun, M. et al. Effects of mesotrione on the control efficiency and chlorophyll fluorescence parameters of Chenopodium album under simulated rainfall conditionss. PLoS ONE https://doi.org/10.1371/journal.pone.0267649 (2022).

Article PubMed PubMed Central Google Scholar

Singh, H., Kumar, D. & Soni, V. Performance of chlorophyll a fluorescence parameters in lemna minor under heavy metal stress induced by various concentration of copper. Sci. Rep. 12(1), 10620. https://doi.org/10.1038/s41598-022-14985-2 (2022).

Article ADS CAS PubMed PubMed Central Google Scholar

Read more:
Growth changes of tomato seedlings responding to sodium salt of ... - Nature.com

New stem cell model developed for treatment of newborn lung … – Innovation Origins

Congenital diaphragmatic hernia is one of the deadliest birth defects. To better understand and treat this condition in the future, an international team of researchers involving Leipzig University Hospital designed a new cell model in the laboratory and tested a drug therapy on it, the institution announced in a press release. The promising results of their recent study have been published in the prestigious American Journal of Respiratory and Critical Care Medicine.

Congenital diaphragmatic hernia (CDH) is a common condition, affecting one in every 2500births. Up to 30per cent of affected babies die from it. The main problem is the underdeveloped lung. The condition also involves a hole in the diaphragm, which paediatric surgeons correct by closing it in the first week of life. Until now, there has been little medical knowledge about how CDH develops what exactly goes wrong during embryonic development. Dr Richard Wagner, a paediatric surgeon and scientist at Leipzig University Hospital, teamed up with researchers from Massachusetts General Hospital in Boston to establish a new patient-specific cell model at Harvard Medical School. Using their model, the researchers investigated possible ways of treating this condition.

German stem cell research has its eye on retinal diseases

Human-induced pluripotent stem cells (HiPSCs) can be used to generate brain organoids that have an ocular structure.

Babies with CDH are placed on a ventilator immediately after birth. We were able to isolate stem cells from the fluid that is sucked out of the childrens lungs and otherwise disposed of, and grow them in the laboratory, explains Dr Wagner, first author of the study. While working as a postdoctoral researcher in the US, the doctor from Leipzig examined the stem cells in the laboratory together with the American researchers, designing cell models of the airways of the tiny patients. This gave them access for the first time to living human lung tissue from patients with CDH. They then compared the stem cells from healthy and underdeveloped lungs.

When the researchers looked at the molecular properties of the stem cells, they found that they had been altered due to inflammation. However, drug therapy in the cell model was able to restore functionality. We also tested this process in animal models and showed that the treatment contributed to better lung development there, too. With the same drug therapy, we were therefore able to achieve positive effects both in human cells in the Petri dish and in the living organism in the established animal model, explains Dr Wagner.

The treatment was performed with the steroid dexamethasone. This drug is already used in clinical practice to induce lung maturity in the foetus when there is a risk of premature birth during pregnancy. What is most appealing is the fact that we already know that this drug is not harmful in pregnancy. If we were to collect more data in laboratory research, it would be possible to investigate later in clinical trials whether there are advantages to administering the drug during pregnancy in order to slow down the possible inflammation in the organism and help the lungs grow, says DrWagner, adding that the aim in future is to be able to intervene with a drug directly after the diagnosis of a diaphragmatic hernia, which happens at around the 20thweek of pregnancy.

Here is the original post:
New stem cell model developed for treatment of newborn lung ... - Innovation Origins

Scientists create mice with two fathers after making eggs from male cells – The Guardian

Genetics

Creation of mammal with two biological fathers could pave way for new fertility treatments in humans

Scientists have created mice with two biological fathers by generating eggs from male cells, a development that opens up radical new possibilities for reproduction.

The advance could ultimately pave the way for treatments for severe forms of infertility, as well as raising the tantalising prospect of same-sex couples being able to have a biological child together in the future.

This is the first case of making robust mammal oocytes from male cells, said Katsuhiko Hayashi, who led the work at Kyushu University in Japan and is internationally renowned as a pioneer in the field of lab-grown eggs and sperm.

Hayashi, who presented the development at the Third International Summit on Human Genome Editing at the Francis Crick Institute in London on Wednesday, predicts that it will be technically possible to create a viable human egg from a male skin cell within a decade. Others suggested this timeline was optimistic given that scientists are yet to create viable lab-grown human eggs from female cells.

Previously scientists have created mice that technically had two biological fathers through a chain of elaborate steps, including genetic engineering. However, this is the first time viable eggs have been cultivated from male cells and marks a significant advance. Hayashis team is now attempting to replicate this achievement with human cells, although there would be significant hurdles for the use of lab-grown eggs for clinical purposes, including establishing their safety.

Purely in terms of technology, it will be possible [in humans] even in 10 years, he said, adding that he personally would be in favour of the technology being used clinically to allow two men to have a baby if it were shown to be safe.

I dont know whether theyll be available for reproduction, he said. That is not a question just for the scientific programme, but also for [society].

The technique could also be applied to treat severe forms of infertility, including women with Turners syndrome, in whom one copy of the X chromosome is missing or partly missing, and Hayashi said this application was the primary motivation for the research.

Others suggested that it could prove challenging to translate the technique to human cells. Human cells require much longer periods of cultivation to produce a mature egg, which can increase the risk of cells acquiring unwanted genetic changes.

Prof George Daley, the dean of Harvard Medical School, described the work as fascinating, but added that other research had indicated that creating lab-grown gametes from human cells was more challenging than for mouse cells. We still dont understand enough of the unique biology of human gametogenesis to reproduce Hayashis provocative work in mice, he said.

The study, which has been submitted for publication in a leading journal, relied on a sequence of intricate steps to transform a skin cell, carrying the male XY chromosome combination, into an egg, with the female XX version.

Male skin cells were reprogrammed into a stem cell-like state to create so-called induced pluripotent stem (iPS) cells. The Y-chromosome of these cells was then deleted and replaced by an X chromosome borrowed from another cell to produce iPS cells with two identical X chromosomes.

The trick of this, the biggest trick, is the duplication of the X chromosome, said Hayashi. We really tried to establish a system to duplicate the X chromosome.

Finally, the cells were cultivated in an ovary organoid, a culture system designed to replicate the conditions inside a mouse ovary. When the eggs were fertilised with normal sperm, the scientists obtained about 600 embryos, which were implanted into surrogate mice, resulting in the birth of seven mouse pups. The efficiency of about 1% was lower than the efficiency achieved with normal female-derived eggs, where about 5% of embryos went on to produce a live birth.

The baby mice appeared healthy, had a normal lifespan, and went on to have offspring as adults. They look OK, they look to be growing normally, they become fathers, said Hayashi.

He and colleagues are now attempting to replicate the creation of lab-grown eggs using human cells.

Prof Amander Clark, who works on lab-grown gametes at the University of California Los Angeles, said that translating the work into human cells would be a huge leap, because scientists are yet to create lab-grown human eggs from female cells.

Scientists have created the precursors of human eggs, but until now the cells have stopped developing before the point of meiosis, a critical step of cell division that is required in the development of mature eggs and sperm. Were poised at this bottleneck at the moment, she said. The next steps are an engineering challenge. But getting through that could be 10 years or 20 years.

{{topLeft}}

{{bottomLeft}}

{{topRight}}

{{bottomRight}}

{{.}}

Read more from the original source:
Scientists create mice with two fathers after making eggs from male cells - The Guardian

Researchers discover therapeutic target to aid in glaucoma treatment – Science Daily

Indiana University School of Medicine researchers have identified a new therapeutic target that could lead to more effective treatment of glaucoma.

Glaucoma is a neurodegenerative disease that causes vision loss and blindness due to a damaged optic nerve. More than 200,000 people are affected by glaucoma in the United States each year. Unfortunately, there is currently no treatment. In a newly published paper in Communications Biology, researchers found neurons use mitochondria for a steady source of energy, and restoring mitochondrial homeostasis in the diseased neurons can protect the optic nerve cells from being damaged.

"Age-related neurodegenerative disease, which includes glaucoma, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), is the biggest global health problem," said Arupratan Das, PhD, assistant professor of ophthalmology and principal investigator of the study. "The fundamental mechanisms that we discovered can be used to protect neurons in glaucoma and be tested for the other diseases. We have identified a critical step of complex mitochondrial homeostasis process, which rejuvenates the dying neuron, similar to giving a lifeline to a dying person."

The research team, led by Michelle Surma and Kavitha Anbarasu from the Department of Ophthalmology, used induced pluripotent stem cells (iPSCs) from patients with and without glaucoma as well as clustered regularly interspaced short palindromic repeats (CRISPR) engineered human embryonic stem cells with glaucoma mutation. Using stem cell differentiated retinal ganglion cells (hRGCs) of the optic nerve, electron microscopy and metabolic analysis, researchers identified glaucomatous retinal ganglion cells suffer mitochondrial deficiency with more metabolic burden on each mitochondrion. This leads to mitochondrial damage and degeneration. Mitochondria are the tube like structures in cells which produce adenosine triphosphate, cell's energy source.

However, the process could be reversed by enhancing mitochondrial biogenesis by a pharmacological agent. The team showed retinal ganglion cells are highly efficient in degrading bad mitochondria, but at the same time producing more to maintain homeostasis.

"Finding that retinal ganglion cells with glaucoma produce more adenosine triphosphate even with less mitochondria was astonishing," Das said. "However, when triggered to produce more mitochondria, the adenosine triphosphate production load was distributed among more mitochondrion which restored the organelle physiology. It is similar to a situation where a heavy stone is carried by fewer people versus a greater number of people -- each person will have less pain and injury, just like each mitochondrion will have less difficulty and damage."

In the future, Das would like to test if these mechanisms protect the optic nerve in animal models under injury before testing in humans to hopefully lead to new clinical interventions.

Go here to see the original:
Researchers discover therapeutic target to aid in glaucoma treatment - Science Daily

Identifying potential treatments for ALS – National Institutes of Health (.gov)

March 7, 2023

Amyotrophic lateral sclerosis, or ALS, is a rare but devastating neurological disease. In ALS, misfolded proteins build up within motor neuronsthe nerve cells in the brain and spinal cord that control voluntary muscle movement. The inability to clear this toxic protein buildup leads to muscle weakness, paralysis, and eventually death.

Some cases of ALS are caused by known, inherited genetic mutations. But most are from sporadic, unknown causes. Rather than target each genetic cause of ALS, researchers have been seeking treatments that could be used across different types. An NIH-funded research team led by Dr. Justin Ichida from the University of Southern California has been searching for cellular processes that couldbe manipulated to treat ALS regardless of the genetic drivers of a persons disease.

The first of two new studies from the team was published in Cell on February 16, 2023. In earlier work, they found that compounds that blocked a protein called PIKFYVE kinase extended the lives of ALS motor neurons. One of these compounds was a small molecule called apilimod.

In their follow-up study, the team tested apilimod in motor neurons with many different drivers of ALS. They also used several genetic methods to shut down PIKFYVE. All methods of PIKFYVE inhibition extended the lives of the various ALS neuron types tested.

Further work teased out the cellular mechanisms responsible for this protective effect. The researchers found that inhibiting PIKFYVE helped neurons clear misfolded, toxic proteins. This happened because a waste-removal process called exocytosis became activated when PIKFYVE was shut down.

The toxic version of a protein called TDP-43 has been linked to ALS and other neurodegenerative diseases. This protein was effectively cleared from the cells through exocytosis after PIKFYVE was inhibited.

When the researchers blocked PIKFYVE in several animal models of ALSincluding mice with a misfolded version of TDP-43motor function was improved, and the animals lived longer.

The teams second study was published on February 2, 2023, in Cell Stem Cell. In that work, the researchers screened a library of almost 2,000 approved drugs and other compounds for their ability to extend the life of ALS motor neurons. They found that some of the most promising compounds altered cellular signaling driven by hormones called androgens (such as testosterone) in the body.

The long-term manipulation of such hormones may have unwanted side effects. So, the researchers searched for other targets that altered gene activity levels in similar ways in motor neurons. Their top candidate was called SFY2.

The team found that suppressing SYF2 levels using genetic techniques increased survival in most types of ALS motor neurons tested, including those that accumulate toxic TDP-43.

In mice, suppressing SYF2 changed the way TDP-43 was exported from the nuclei of cells. This stopped the buildup of toxic protein clumps within neurons. Reducing the amount of SYF2 in the mice improved motor functioning as well.

Our discoveries bring us closer to achieving our big picture goal: finding treatments that can be broadly effective for all patients who suffer from ALS, Ichida says.

Before these approaches could be tested in people, future work will be needed to identify the safest ways to suppress such cellular pathways.

by Sharon Reynolds

References:PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. Hung ST, Linares GR, Chang WH, Eoh Y, Krishnan G, Mendonca S, Hong S, Shi Y, Santana M, Kueth C, Macklin-Isquierdo S, Perry S, Duhaime S, Maios C, Chang J, Perez J, Couto A, Lai J, Li Y, Alworth SV, Hendricks E, Wang Y, Zlokovic BV, Dickman DK, Parker JA, Zarnescu DC, Gao FB,Ichida JK. Cell. 2023 Feb 16;186(4):786-802.e28. doi: 10.1016/j.cell.2023.01.005. Epub 2023 Feb 7. PMID:36754049.

SYF2 suppression mitigates neurodegeneration in models of diverse forms of ALS. Linares GR, Li Y, Chang WH, Rubin-Sigler J, Mendonca S, Hong S, Eoh Y, Guo W, Huang YH, Chang J, Tu S, Dorjsuren N, Santana M, Hung ST, Yu J, Perez J, Chickering M, Cheng TY, Huang CC, Lee SJ, Deng HJ, Bach KT, Gray K, Subramanyam V, Rosenfeld J, Alworth SV, Goodarzi H,Ichida JK. Cell Stem Cell. 2023 Feb 2;30(2):171-187.e14. doi: 10.1016/j.stem.2023.01.005.PMID:36736291.

Funding:NIHs National Institute of Neurological Disorders and Stroke (NINDS); US Department of Defense; Donald E. and Delia B. Baxter Foundation; Tau Consortium; Ford Foundation; Muscular Dystrophy Association; New York Stem Cell Foundation; Alzheimer's Drug Discovery Foundation; Association for Frontotemporal Degeneration; Pape Adams Foundation; John Douglas French Alzheimer's Foundation; Harrington Discovery Institute; Milken Family Foundation; USC Broad Innovation Award; Southern California Clinical and Translational Science Institute; Keck Medicine of USC; Target ALS Foundation; John Douglas French Alzheimers Foundation; Broad Institute; ALS Association; Lawrence and Isabel Barnett Drug Development Award; Frick Foundation for ALS Research; University of Southern California Alzheimers Disease Research Center; California Institute for Regenerative Medicine.

Visit link:
Identifying potential treatments for ALS - National Institutes of Health (.gov)

Exciting Cell & Gene Therapy Research Updates in Glaucoma and … – geneonline

Exciting Cell & Gene Therapy Research Updates in Glaucoma and Nerve Regeneration

As the Cell & Gene Therapy Research & Development Congress 2023 entered its second day, experts from around the world continued to share their latest exciting research findings and possible future directions in the related fields.

Day two of the event began with a virtual keynote address themed Gene Therapy for Glaucoma by Paul Kaufman, MD, Professor of Ophthalmology & Visual Sciences at the University of Wisconsin-Madison School of Medicine & Public Health. As an incurable, age-related degenerative optic neuropathy, glaucoma affects approximately 80 million people globally and is one of the worlds leading causes of preventable blindness. In most cases, the disease is caused by a buildup of fluid in the front part of the eye, which elevates intraocular pressure (IOP), causing damage to the optic nerve and possibly leading to permanent vision loss. With this in mind, lowering IOP is the top priority in devising ways to treat glaucoma and prevent disease progression.

Following an overview of glaucoma, professor Kaufman introduced some new approaches to managing the disease, with an emphasis on modifying the aqueous humor dynamics in the eye, such as encapsulated cell technology (ECT) and devices for micro-invasive glaucoma surgery (MIGS). Then he focused on the development of gene therapy for glaucoma and the findings obtained by his research team.

Related Article: Cell & Gene Therapy Congress Asia Day One: Advances in the Research

Theoretically, it is possible for gene therapies to achieve IOP reduction and preserve vision by different means such as protecting neurons of the optic nerve, decreasing aqueous humor production and enhancing aqueous humor outflow.

With an interest in the mechanisms of aqueous humor formation and drainage, Prof. Kaufmans team sets their strategy to go after the physiology of the system, focusing on the trabecular meshwork (TM) and the uveoscleral pathway for outflow enhancement. They aim at identifying genes that would act on cells involved in these pathways so as to increase the fluid flow in the eye without actually replacing a gene that happens to be defective. Ultimately, their goal is to deliver a gene into the tissues and obtain a long-lasting therapeutic effect, allowing patients to avoid using time-consuming daily treatments

The team hypothesizes that in live non-human primates (NHPs), administration of viral vector-transgene constructs incorporating the C3 transferase or caldesmon transgene directly into Schlemms canal will decrease conventional aqueous humor outflow resistance and thereby reduce intraocular pressure.

Professor Kaufman also shared the research findings regarding the Wnt signaling pathway in human TM cells, showing that restoring the overexpression of certain proteins in this pathway may be a possible way for IOP reduction, thereby treating glaucoma.

Towards the end of his presentation, Professor Kaufman also mentioned current constraints and challenges of gene therapy for glaucoma, including vector-associated side effects (toxicity), difficulties in turning on or off the gene, gene-targeting technology, regulatory hurdles as well as the gap between theories and experimental observations that have yet to be resolved. Nevertheless, he still feels hopeful that the current research findings may provide insights for developing potential human therapeutics and that they could eventually move into the pre-drug phase and become part of a clinical trial.

The second keynote speech of the day was delivered by professor Ing-Ming Chiu, Chair Professor at Graduate Institute of Biomedical Sciences at China Medical University, with the theme Neural Stem Cells and Neurotrophic Factors in Nerve Regeneration.

Since the discovery of the regeneration of neurons after birth in animals, scientists around the world have been engaging in neural stem cell (NSC) research. It has been found that fibroblast growth factors FGF1 and FGF2 are required for the maintenance of NSCs in early development.

Moreover, FGF1 and interleukin 12 (IL12), separately, are beneficial in nerve repair via promoting axonal growth. With the sciatic nerve injury mouse model, Prof. Chius team has found that the implantation of NSCs combined with nerve conduit and IL12 can increase neuroregeneration and improve motor recovery.

IL12 is a dimeric protein that is formed by the combination of p35 and p40 subunits. In particular, the team has found that mouse IL12p80 (homodimer of two p40 subunits) facilitates nerve regeneration and promotes functional recovery in vivo. In vitro studies of the molecular mechanism reveal that IL12p80 stimulates the Schwann cell differentiation of mouse NSCs through the phosphorylation of Stat3 in NSCs.

Furthermore, the team later used human IL12p80 in mouse models and it has been found that hIL12p80 also facilitates nerve regeneration in mice. One of their ongoing studies involves an attempt of using hIL12 and human nerve in the mouse model. In the event that positive outcomes are achieved, these findings may provide insights for developing potential therapies for neurological diseases in humans.

Developments in Regenerative Medicine: Gene Delivery Tools and Cell Therapy for Parkinsons Disease

2023-03-08

Revolutionizing Eye Disease Treatment with iPSC Therapy

2023-03-07

Global Head of Research of Kite Pharma Unveiled the Key Elements to Success in Adoptive Cell Therapy

2023-03-07

See original here:
Exciting Cell & Gene Therapy Research Updates in Glaucoma and ... - geneonline